Gastrointestinal problems affect the GI tract from the mouth to the anus. It is a set of disorders that rise in the digestive tract.
Here is a list of the latest approaches to treat gastrointestinal issues.
New Treatment Introduced
- The new treatment paradigm targets cellular and molecular defects.
- The treatment of FGIDs has undergone a substantial paradigm shift in recent years from symptomatic treatment to subtyping of the condition and the underlying pathophysiology.
Current Modulations
- The currently modulated pathophysiological mechanisms include prokinetic agents like (5-HT4R) agonists, ghrelin receptor agonists, (HT3R) antagonists, (5-HT1AR) agonists and muscarinic receptor antagonists.
New Mechanisms
- New mechanisms include motility for altered gut, mast cell stabilizer for gut immune dysfunction, acid suppression therapy and histamine receptor-1 (HRH1) antagonists for impaired duodenal clearance of gastric acid and visceral hypersensitivity, (CB2R) agonist for visceral pain, chloride channel 2 (CCL2) and guanylate cyclase-C (GC-C) receptor agonists for altered GI secretion, farnesoid X receptor (FXR) agonist and ileal bile acid transporter (IBAT) antagonist for altered BA secretion, central and visceral neuromodulators, (TCA), (TeCA), (SNRIs), (SSRIs) for altered gut-brain axis.
